Likelihood of Approval and Phase Transition Success Rate Model – Novaferon in Coronavirus Disease 2019 (COVID-19)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Novaferon in Coronavirus Disease 2019 (COVID-19) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Novaferon in Coronavirus Disease 2019 (COVID-19) Drug Details:
Novaferon is a interferon act as immunostimulant agent. It is formulated as injectable solution for intramuscular route of administration. Novaferon is indicated for the treatment of HBeAg-positive chronic hepatitis B, patients with advanced cancer: used to extend survival and improve quality of life, in combination with chemotherapy: the treatment of patients with common malignancies, after tumor surgery or for cancer chemotherapy patients: to prevent cancer recurrence and metastasis, thereby improving the cure rate and survival rate of cancer patients, for cancer prevention: novaferon due to adverse events was a transient, and therefore expected to relatively healthy, negative imaging, but the tumor-associated individual crowd abnormalities in regular use of low doses to reduce the cancer marker levels, to prevent and reduce the incidence of malignant tumors, viral infections, such as Hepatitis C, avian influenza, HIV (AIDS) and genital wart, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and other autoimmune diseases.Novaferon is under development for the treatment of Coronavirus disease 2019 (COVID-19). The drug candidate is administered through intramuscular. It was also under development for metastatic neuroendocrine tumors, metastatic colorectal cancer, pancreatic cancer, melanoma, liver cancer, gastric cancer, non-small cell lung cancer, rheumatoid arthritis and breast cancer.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Novaferon LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports